Books
in black and white
Main menu
Share a book About us Home
Books
Biology Business Chemistry Computers Culture Economics Fiction Games Guide History Management Mathematical Medicine Mental Fitnes Physics Psychology Scince Sport Technics
Ads

biopharmaceuticals biochemistry and biotecnology - Walsh G.

Walsh G. biopharmaceuticals biochemistry and biotecnology - John Wiley & Sons, 2003. - 572 p.
ISBN 0-470-84327-6
Download (direct link): biochemistryandbiotechnology2003.pdf
Previous << 1 .. 116 117 118 119 120 121 < 122 > 123 124 125 126 127 128 .. 292 >> Next

Karupiah, G. (1997). Gamma Interferon in Antiviral Defence. Landes Bioscience, Lewisville, TX. Mantovani, A. (2000). Pharmacology of Cytokines. Oxford University Press, Oxford.
Mire-Sluis, A. (1998). Cytokines. Academic Press, London.
Reder, A. (1996). Interferon Therapy of Multiple Sclerosis. Marcel Dekker, New York.
Articles
Cytokines—general
Aringer, M. et al. (1999). Interleukin/interferon signalling — a 1999 perspective. Immunologist 7(5), 139-146. Baggiolini, M. et al. (1997). Human chemokines — an update. An. Rev. Immunol. 15, 675-705.
Dardenne, M. & Savino, W. (1996). Interdependence of the endocrine and immune systems. Adv. Neuroimmunol. 6(4), 297-307.
Debetes, R. & Savelkoul, H. (1996). Cytokines as cellular communicators. Mediat. Inflamm. 5(6), 417-423.
Henderson, B. & Wilson, M. (1996). Cytokine induction by bacteria—beyond lipopolysaccharide. Cytokine 8(4), 269282.
Ihle, J. (1996). STATs: signal transducers and activators of transcription. Cell 84, 331-334.
Kishimoto, T. et al. (1994). Cytokine signal transduction. Cell 76, 253-262.
Lau, F. & Horvath, C. (2002). Mechanisms of type I interferon cell signalling and STAT-mediated transcriptional responses. Mt Sinai J. Med. 69(3), 156-168.
Liu, L. et al. (1997). Ship, a new player in cytokine-induced signalling. Leukaemia 11(2), 181-184.
Mire-Sluis, A. (1999). Cytokines: from technology to therapeutics. Trends Biotechnol. 17, 319-325.
O’Shea, J.J. et al. (2002). Cytokine signalling in 2002: new surprises in the JAK-STAT pathway. Cell 109, S121-S131. Piscitelli, S. et al. (1997). Pharmacokinetic studies with recombinant cytokines — scientific issues and practical considerations. Clin. Pharmacokinet. 32(5), 368-381.
Poole, S. (1995). Cytokine therapeutics. Trends Biotechnol. 13, 81-82.
Proost, P. et al. (1996). The role of chemokines in inflammation. Int. J. Clin. Lab. Res. 26(4), 211-223.
Schooltink, H. & Rose, J. (2002). Cytokines as therapeutic drugs. J. Interferon Cytokine Res. 22(5), 505-516.
Takatsu, K. (1997). Cytokines involved in B cell differentiation and their sites of action. Proc. Soc. Exp. Biol. Med. 215(2), 121-133.
Taniguchi, T. (1995). Cytokine signalling through non-receptor protein tyrosine kinases. Science 268, 251-255.
Interferons
Alberti, A. (1999). Interferon acon-1. A novel interferon for the treatment of chronic hepatitis C. Biodrugs 12(5), 343357.
Belardelli, F. et al. (2002). Interferon-a in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 119-134.
Boehm, U. et al. (1997). Cellular responses to interferon-g. Ann. Rev. Immunol. 15, 749-795.
Brassard, D. et al. (2002). Interferon-a as an immunotherapeutic protein. J. Leukocyte Biol. 71(4), 565-581.
Cencic, A. & La Bonnardiere, C. (2002). Trophoblastic interferon-g: current knowledge and possible role in early pig pregnancy. Vet. Res. 33(2), 139-157.
Chelmonska-Soyta, A. (2002). Interferon-t and its immunological role in ruminant reproduction. Arch. Immunol. Ther. Exp. 50(1), 47-52.
Colonna, M. et al. (2002). Interferon-producing cells: on the front line in immune responses against pathogens. Curr.
Opin. Immunol. 14(3), 373-379.
Haria, M. & Benfield, P. (1995). Interferon-a2A. Drugs 50(5), 873-896.
Jonasch, E. & Haluska, F. (2001). Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist 6(1), 34-55.
Katre, N. (1993). The conjugation of proteins with polyethylene glycol and other polymers — altering properties of proteins to enhance their therapeutic potential. Adv. Drug Delivery Rev. 10(1), 91-114.
Kirkwood, J. (2002). Cancer immunotherapy: the interferon-a experience. Semin. Oncol. 29(3), 18-26.
Leaman, D. et al. (1996). Regulation of STAT-dependent pathways by growth factors and cytokines. FASEB J. 10(14), 1578-1588.
Li, J. & Roberts, M. (1994). Interferon-t and interferon-a interact with the same receptors in bovine endometrium. J.
Biol. Chem. 269(18), 13544-13550.
Lyseng-Williamson, K. & Plosker, G. (2002). Management of relapsing-remitting multiple sclerosis — defining the role of subcutaneous recombinant interferon-b-1a (Rebif). Dis. Managem. Health Outcomes 10(5), 307-325.
THE CYTOKINES—THE INTERFERON FAMILY 221
Meager, A. (2002). Biological assays for interferons. J. Immunol. Methods 261(1-2), 21-36.
Pestka, S. & Langer, J. (1987). Interferons and their actions. Ann. Rev. Biochem. 56, 727-777.
Simko, R. & Nagy, K. (1996). Interferon-a in childhood hematological malignancies. Postgrad. Med. J. 72(854), 709713.
Soos, J. & Johnson, H. (1999). Interferon-t. Prospects for clinical use in autoimmune disorders. BioDrugs 11(2), 125-135. Todd, P. & Goa, K. (1992). Interferon-g-1b. Drugs 43(1), 111-122.
Tossing, G. (2001). New developments in interferon therapy. Eur. J. Med. Res. 6(2), 47-65.
Wang, Y. et al. (2002). Structural and biological characterization of PEGylated recombinant interferon-a2B and its therapeutic implications. Adv. Drug Delivery Rev. 54(4), 547-570.
Previous << 1 .. 116 117 118 119 120 121 < 122 > 123 124 125 126 127 128 .. 292 >> Next